Abstract 5664: A novel immunotherapy for relapsed/refractory acute lymphoblastic leukemia (ALL)
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-5664
Abstract: Successful treatment of ALL has been a major feat of modern medicine. Overall, 5-year survival in pediatric ALL patients approaches 90%, but 10-15% of patients will relapse. In relapse, ALL is still challenging to cure… read more here.
Keywords: refractory acute; relapsed refractory; novel; acute lymphoblastic ... See more keywords